AR082906A1 - Parches transdermicos de dosis baja con nivel elevado de liberacion de droga - Google Patents
Parches transdermicos de dosis baja con nivel elevado de liberacion de drogaInfo
- Publication number
- AR082906A1 AR082906A1 ARP110103249A ARP110103249A AR082906A1 AR 082906 A1 AR082906 A1 AR 082906A1 AR P110103249 A ARP110103249 A AR P110103249A AR P110103249 A ARP110103249 A AR P110103249A AR 082906 A1 AR082906 A1 AR 082906A1
- Authority
- AR
- Argentina
- Prior art keywords
- drug
- transdermic
- patches
- dose
- low
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title abstract 5
- 239000010410 layer Substances 0.000 abstract 4
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 abstract 2
- 229960002568 ethinylestradiol Drugs 0.000 abstract 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 abstract 1
- 229920002367 Polyisobutene Polymers 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000012790 adhesive layer Substances 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
La presente se relaciona con el campo de las técnicas de formulación farmacéutica.Reivindicación 1: Sistema terapéutico transdérmico, caracterizado porque contiene: a) una capa de soporte; b) al menos una capa adhesiva que contiene droga que comprende los ingredientes activos gestodeno y etinilestradiol en una matriz que contiene poliisobutileno e ingredientes farmacéuticamente aceptables, c) un revestimiento de separación y donde la cantidad de gestodeno comprende entre aproximadamente 0,4 y 1,95% en peso de la capa que contiene droga y la cantidad de etinilestradiol es del 0,5% (p/p) en peso de la capa que contiene droga, donde la cantidad preferida de gestodeno comprende entre aproximadamente 0,9 y 1,5% en peso de la capa que contiene droga.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10175498 | 2010-09-06 | ||
| EP11155469 | 2011-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082906A1 true AR082906A1 (es) | 2013-01-16 |
Family
ID=44653287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103249A AR082906A1 (es) | 2010-09-06 | 2011-09-06 | Parches transdermicos de dosis baja con nivel elevado de liberacion de droga |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8671945B2 (es) |
| EP (1) | EP2613772B1 (es) |
| CN (1) | CN103189064B (es) |
| AR (1) | AR082906A1 (es) |
| CY (1) | CY1118684T1 (es) |
| DK (1) | DK2613772T3 (es) |
| ES (1) | ES2617334T3 (es) |
| HR (1) | HRP20170292T1 (es) |
| HU (1) | HUE031326T2 (es) |
| LT (1) | LT2613772T (es) |
| ME (1) | ME02618B (es) |
| PL (1) | PL2613772T3 (es) |
| PT (1) | PT2613772T (es) |
| RS (1) | RS55681B1 (es) |
| SI (1) | SI2613772T1 (es) |
| TW (1) | TW201215393A (es) |
| UY (1) | UY33593A (es) |
| WO (1) | WO2012031999A2 (es) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4081537A (en) | 1975-10-10 | 1978-03-28 | Schering Aktiengesellschaft | Δ15 -Steroids and pharmaceutical compositions thereof |
| CH674618A5 (es) | 1987-04-02 | 1990-06-29 | Ciba Geigy Ag | |
| ES2081823T3 (es) | 1988-10-27 | 1996-03-16 | Schering Ag | Agente para la aplicacion transdermica, que contiene gestoden. |
| JPH06502419A (ja) | 1990-10-29 | 1994-03-17 | アルザ・コーポレーション | 経皮避妊製剤、方法及びデバイス |
| US5512292A (en) | 1990-10-29 | 1996-04-30 | Alza Corporation | Transdermal contraceptive formulations methods and devices |
| DE4336557C2 (de) | 1993-05-06 | 1997-07-17 | Lohmann Therapie Syst Lts | Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung |
| DE4405898A1 (de) | 1994-02-18 | 1995-08-24 | Schering Ag | Transdermale therapeutische Systeme enthaltend Sexualsteroide |
| DE19527925C2 (de) * | 1995-07-29 | 1997-07-03 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit einer trennmittelbeschichteten Schutzschicht |
| DE19827732A1 (de) | 1998-06-22 | 1999-12-23 | Rottapharm Bv | Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie |
| DE19906152B4 (de) * | 1999-02-10 | 2005-02-10 | Jenapharm Gmbh & Co. Kg | Wirkstoffhaltige Laminate für Transdermalsysteme |
| WO2002045701A2 (en) | 2000-12-05 | 2002-06-13 | Noven Pharmaceuticals, Inc. | Crystallization inhibition of drugs in transdermal drug delivery systems |
| WO2002102390A1 (en) * | 2001-06-18 | 2002-12-27 | Noven Pharmaceuticals, Inc. | Enhanced drug delivery in transdermal systems |
| DE10261696A1 (de) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
| HRP20050828B1 (hr) * | 2003-02-21 | 2013-10-25 | Bayer Intellectual Property Gmbh | Uv-stabilni transdermalni flaster |
| CA2536984C (en) | 2003-08-25 | 2013-07-23 | Bfs Diversified Products, Llc | Method and apparatus to monitor the compressive strength of insulation boards |
| EP1541136A1 (de) * | 2003-12-10 | 2005-06-15 | Schering AG | UV-Licht stabile halbfeste transdermale Systeme, die einen lichtempfindlichen Wirkstoff und einen UV-Absorber enthalten |
| US8668925B2 (en) * | 2003-12-12 | 2014-03-11 | Bayer Intellectual Property Gmbh | Transdermal delivery of hormones without the need of penetration enhancers |
| NZ548091A (en) | 2003-12-12 | 2009-12-24 | Bayer Schering Pharma Ag | Transdermal delivery system of hormones without penetration enhancers |
| UA89766C2 (en) | 2003-12-12 | 2010-03-10 | Байер Шеринг Фарма Акциенгезельшафт | Transdermal delivery system of gestodene |
| EP1719504A1 (de) | 2005-05-02 | 2006-11-08 | Schering AG | Festes transdermales therapeutisches System mit UV-Absorber |
| US20100086582A1 (en) | 2008-10-06 | 2010-04-08 | Mylan Technologies, Inc. | Amorphous rotigotine transdermal system |
-
2011
- 2011-09-05 SI SI201131114A patent/SI2613772T1/sl unknown
- 2011-09-05 ME MEP-2017-54A patent/ME02618B/me unknown
- 2011-09-05 DK DK11757811.2T patent/DK2613772T3/en active
- 2011-09-05 WO PCT/EP2011/065261 patent/WO2012031999A2/en not_active Ceased
- 2011-09-05 HR HRP20170292TT patent/HRP20170292T1/hr unknown
- 2011-09-05 PL PL11757811T patent/PL2613772T3/pl unknown
- 2011-09-05 ES ES11757811.2T patent/ES2617334T3/es active Active
- 2011-09-05 RS RS20170194A patent/RS55681B1/sr unknown
- 2011-09-05 EP EP11757811.2A patent/EP2613772B1/en not_active Revoked
- 2011-09-05 PT PT117578112T patent/PT2613772T/pt unknown
- 2011-09-05 CN CN201180053091.XA patent/CN103189064B/zh not_active Expired - Fee Related
- 2011-09-05 LT LTEP11757811.2T patent/LT2613772T/lt unknown
- 2011-09-05 HU HUE11757811A patent/HUE031326T2/hu unknown
- 2011-09-06 AR ARP110103249A patent/AR082906A1/es unknown
- 2011-09-06 UY UY0001033593A patent/UY33593A/es unknown
- 2011-09-06 US US13/225,829 patent/US8671945B2/en not_active Expired - Fee Related
- 2011-09-06 TW TW100132152A patent/TW201215393A/zh unknown
-
2017
- 2017-03-01 CY CY20171100272T patent/CY1118684T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2613772T3 (en) | 2017-03-06 |
| HRP20170292T1 (hr) | 2017-04-21 |
| PT2613772T (pt) | 2017-03-06 |
| US20120073578A1 (en) | 2012-03-29 |
| RS55681B1 (sr) | 2017-07-31 |
| WO2012031999A2 (en) | 2012-03-15 |
| CN103189064B (zh) | 2015-08-12 |
| CN103189064A (zh) | 2013-07-03 |
| TW201215393A (en) | 2012-04-16 |
| HUE031326T2 (hu) | 2017-07-28 |
| PL2613772T3 (pl) | 2017-06-30 |
| WO2012031999A3 (en) | 2012-08-02 |
| EP2613772B1 (en) | 2016-12-14 |
| ME02618B (me) | 2017-06-20 |
| HK1186968A1 (en) | 2014-03-28 |
| CY1118684T1 (el) | 2017-07-12 |
| US8671945B2 (en) | 2014-03-18 |
| EP2613772A2 (en) | 2013-07-17 |
| LT2613772T (lt) | 2017-03-27 |
| SI2613772T1 (sl) | 2017-03-31 |
| UY33593A (es) | 2012-04-30 |
| ES2617334T3 (es) | 2017-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2528650T3 (es) | Sistema terapéutico transdérmico que comprende buprenorfina | |
| CL2019000431A1 (es) | Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814) | |
| CY1116638T1 (el) | Διαδερμικο θεραπευτικο συστημα για την χορηγηση μιας δραστικης ουσιας | |
| AR093481A1 (es) | Parche de varios dias para la administracion transdermica de rotigotina | |
| AR073704A1 (es) | Sistema de administracion transdermal de droga para principios activos liquidos que tiene una capa de matriz adhesiva que incluye un ingrediente farmaceutico activo que es seleccionado entre selegilina y rivastigmina | |
| BRPI1007945C8 (pt) | formulação farmacêutica de liberação controlada de nitazoxanida, tizoxanida ou uma combinação dos mesmos, e, comprimido de bicamada para administração oral | |
| ECSP10010395A (es) | Formulacion de capsula | |
| AR097045A2 (es) | Sistema terapéutico transdérmico | |
| AR061771A1 (es) | Sistema de administracion terapeutica | |
| AR064268A1 (es) | Sistema terapeutico transdermico para administracion del principio activo buprenorfina | |
| PE20120584A1 (es) | Preparaciones farmaceuticas transdermicas | |
| MX2012002727A (es) | Sistema terapeutico transdermico para administrar fentanilo o un analogo del mismo. | |
| ES2570205T3 (es) | Sistema terapéutico transdérmico con pequeña tendencia a la cristalización espontánea | |
| CL2010000524A1 (es) | Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales. | |
| BR112015024271A2 (pt) | sistema de fornecimento transdérmico | |
| UY32109A (es) | Métodos para utilizar composiciones de liberación sostenida de aminopiridina | |
| MX2017013636A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas. | |
| JP2014520867A (ja) | ジクロフェナクおよびチオコルチコシドを含有する貼付剤 | |
| BR112012014107B8 (pt) | sistema terapêutico transdérmico (tts) e processo de produção de tts | |
| CL2013003176A1 (es) | Formulacion farmaceutica oral de liberacion sostenida que comprende dos tabletas que contienen 1000 mg de paracetamol, el cual esta presente en una capa de liberacion sostenida y otra de liberacion inmediata, en una proporcion de paracetamol por capa de 80-90 %: 10-20 %, donde la dosis unitaria comprende 2000 mg de paracetamol. | |
| WO2012111996A3 (ko) | 갈란타민 또는 그의 염을 함유하는 경피흡수제제 | |
| JP2016513665A5 (es) | ||
| AR082906A1 (es) | Parches transdermicos de dosis baja con nivel elevado de liberacion de droga | |
| AR086491A1 (es) | Composicion farmaceutica que comprende fexofenadina | |
| MX2017013643A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |